Galantamine, which was found to reduce cocaine use in patients treated with methadone for opioid use disorder, may also be effective in reducing the use of nonprescribed opioids in this population.
The US Food and Drug Administration is seeking feedback from healthcare professionals on its proposal to offer fixed-quantity blister packaging for a select number of opioid medications.
Buprenorphine treatment may be more available to individuals who are white, use self-pay, or have private insurance.
The prevalence of cluster headache may be higher in individuals with a substance use disorder than in the general population.
Expanded Medicaid eligibility thresholds were associated with a reduction in substance use disorder-related deaths during the current US opioid epidemic.
Physicians reported that a lack of training in brief intervention and reimbursement make providing screening and intervention more difficult when caring for youth with possible substance use disorders.
A substantial proportion of adolescent and young adults receiving opioids for dental procedures may be at higher risk for later opioid use and abuse.
From 2007 to 2016, there was a sharp increase in pregnancy-associated mortality involving opioids.
Warning letters about products illegally marketed as treatments for opioid addiction, pain, and anxiety have been sent to two companies from the FDA.
Clinicians who are highly concerned about opioid misuse, addiction, and psychological dependence may be more confident but also more reluctant to prescribe opioids.
